Comparative Pharmacology
Head-to-head clinical analysis: LEVOCETIRIZINE HYDROCHLORIDE versus PROMETHAZINE DM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVOCETIRIZINE HYDROCHLORIDE versus PROMETHAZINE DM.
LEVOCETIRIZINE HYDROCHLORIDE vs PROMETHAZINE DM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levocetirizine is a selective peripheral histamine H1-receptor antagonist. It inhibits the effects of histamine at the H1 receptor, reducing allergic symptoms such as itching, sneezing, and rhinorrhea. It has lower affinity for central H1 receptors and anticholinergic properties compared to first-generation antihistamines.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, antiemetic via blockade of dopamine D2 receptors in the chemoreceptor trigger zone, and sedative via central anticholinergic effects. Dextromethorphan is an NMDA receptor antagonist and sigma-1 receptor agonist, suppressing cough by central action on the cough center.
Oral, 5 mg once daily in the evening.
2 teaspoonfuls (10 mL) orally every 4-6 hours, not to exceed 8 teaspoonfuls (40 mL) per 24 hours.
None Documented
None Documented
Terminal elimination half-life: 7–8 hours in healthy adults; prolonged to 20–24 hours in renal impairment (CrCl <40 mL/min); clinically, stable levels require 2–3 days.
16-19 hours (terminal); note: effect may last longer due to active metabolites and tissue binding
Approximately 85% renal excretion as unchanged drug via glomerular filtration and tubular secretion, 12.9% fecal excretion, <1% biliary.
Renal (70-80% as metabolites, <1% unchanged); biliary/fecal (20-30%)
Category A/B
Category A/B
Antihistamine
Antihistamine / Antiemetic